- AmbioPharm is expanding its North Augusta, South Carolina facility by 68,000 square feet to support commercial-scale peptide manufacturing.
- The expansion aims to enhance CDMO capabilities for complex peptide programs, including SPPS, LPPS, and hybrid synthesis.
AmbioPharm has announced an expansion of its manufacturing facility in North Augusta, South Carolina, adding 68,000 square feet of new space to support peptide API development and contract manufacturing.
The expansion is designed to accommodate full upstream commercial synthesis and flexible manufacturing approaches, including solid-phase peptide synthesis (SPPS), liquid-phase peptide synthesis (LPPS), and hybrid synthesis. The site is intended to support late-stage and commercial-scale peptide programs.
The company stated that the investment is part of its strategy to strengthen its U.S. manufacturing footprint and respond to demand from partners developing peptide-based therapies. The project is being advanced alongside discussions with state, local, and federal authorities regarding potential support for life sciences manufacturing.
AmbioPharm said the expanded facility will enable shorter lead times, smoother technology transfer, and dual-site flexibility, while supporting scalability and consistent quality for complex peptide projects.
“We have spoken with our client-partners about their growth, their challenges, and the pressures they face to move promising therapies forward without delay.”
Brian Gregg, CEO of AmbioPharm
